/Announcement of Resolutions of the 18th Meeting of the Ninth Board of Directors of Tasly

NEWS

Announcement of Resolutions of the 18th Meeting of the Ninth Board of Directors of Tasly

Shanghai Stock Exchange

2026/03/20

Stock code: 600535 Stock abbreviation: Tasly Announcement number: Lin No. 2026-004

Tasly Pharmaceutical Group Co., Ltd.

Announcement of Resolutions of the 18th Meeting of the Ninth Board of Directors

The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.

The notice of the 18th meeting of the ninth session of the Board of Directors of Tasly Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Tasly" or the "Company") was issued in writing on March 8, 2026. The meeting was held at 14:00 pm on March 18, 2026 at the China Resources Learning and Innovation Center (Xiongan Campus) in a combination of live and video. The meeting was supposed to be attended by 15 directors, who were actually present. 14 people. Director Mr. Wang Liang entrusted director Mr. Wang Ke in writing to exercise voting rights on his behalf due to work reasons. Some senior executives of the company attended the meeting. The meeting complied with the relevant provisions of the Company Law and the Articles of Association, and was legal and valid. The meeting was chaired by Ms. Zhou Hui, the company’s chairman. After deliberation by the participants, the following proposals were adopted:

1. Proposal on the company’s “15th Five-Year Plan” strategic plan

(1) Strategic planning background

During the "15th Five-Year Plan" period, China's pharmaceutical market will enter a new stage of development with "equal emphasis on quality and efficiency, and diversified innovation". Innovation leadership, value-driven professional promotion, refined management and control of production costs, collaborative management of in-hospital and out-of-hospital markets, and AI digital empowerment of the entire industry chain have become key elements to drive high-quality development of the industry. As an important part of China Resources Sanjiu's "One Body and Two Wings", Tasly seizes industry development opportunities, bases on its own advantages, formulates the company's "15th Five-Year Plan" strategic plan, and builds new growth space and new development momentum.

(2) Corporate mission, corporate vision, and strategic goals

Corporate mission: Create health and share it with everyone

"Creating health for everyone" is Tasly's lofty mission based on public health. The company is not only committed to providing drugs with high clinical value to fight diseases and protect the quality of life; it also shoulders the social responsibility of making advanced medical achievements transcend limitations and benefit every individual, making health accessible to everyone.

Corporate vision: Driven by innovation, become a leading company in the Chinese pharmaceutical market

Tasly takes national strategies and industry trends as its development guidance, all-round innovation as its development driving force, and industry leadership as its development goal. At the critical stage of high-quality development in the pharmaceutical industry, Tasly actively responds to the national policy of encouraging innovation and creates an "open innovation system driven by two wheels of innovative traditional Chinese medicine and advanced therapeutic drugs". Through R&D innovation, technology iteration and model upgrading, Tasly builds sustained growth and competitiveness. While pursuing growth in business scale, it has taken the lead in cutting-edge technology application, business model shaping and corporate governance effectiveness, becoming an important force in promoting the upgrading of China's pharmaceutical industry.

Strategic goals: During the "15th Five-Year Plan" period, the company will adhere to the innovation drive, focus on the "3+1" disease field, build a value cycle business model, and strive to double its industrial operating revenue (reaching 15 billion) and profits by the end of 2030 through both endogenous development and external expansion, and successfully rank among the first echelon of Chinese pharmaceutical companies.

(3) Business areas, business models, and strategic initiatives

Business areas

Based on the population change trend and evolving characteristics of the disease spectrum, the company combines its own R&D technology advantages and commercialization foundation to focus on the "3+1" disease field, that is, taking the three disease fields of cardiovascular and metabolic, neurological/psychiatric, and digestive diseases as the core. It also considers pipeline layout and future market opportunities, and chooses opportunities to develop the fourth disease field. In addition, a comprehensive evaluation was conducted for each core disease area to further screen out several subdivided diseases with high potential.

Business model

The company adopts a closed-loop business model of "building foundation inside the hospital and increasing efficiency outside the hospital" to build a sustainable value cycle. The foundation of the hospital is based on "high clinical value innovation + medical-led academic promotion". By developing innovative products with clear clinical advantages, relying on professional medical research and academic promotion, we ensure the recognition and priority use of products in medical institutions, and achieve efficient implementation from research and development to commercialization. The core of out-of-hospital efficiency enhancement is "accepting in-hospital prescriptions + multi-touch point closed loop throughout the patient journey", effectively accepting prescriptions extended from the hospital through diversified channels (such as DTP pharmacies, Internet hospitals, retail pharmacies, etc.), providing patient services, and achieving long-term repurchase. The solid clinical foundation within the hospital provides prescription sources and brand potential for market expansion outside the hospital; the efficient patient services and channel coverage outside the hospital further consolidate and amplify the value within the hospital, forming a closed business loop of mutual promotion and sustainable growth.

Strategic initiatives

In order to ensure the full realization of strategic goals, the company has clarified nine key strategic measures, built eight core capabilities, and consolidated five major organizational guarantees. The nine key strategic initiatives focus on the core tasks of achieving breakthroughs, including improving R&D efficiency, quickly replenishing the innovation pipeline, optimizing the cost of the entire industry chain, deepening professional promotion, strategic breakthroughs in sales scale, increasing the scale of digital business, integrating high-quality resources in the industry, improving AI-enabled business and management efficiency, and creating a talent echelon that meets strategic needs. The implementation of these measures aims to seize strategic opportunities and focus the company's future development on innovation-driven, professional and intelligent digital transformation. At the same time, the company strives to build eight core capabilities, covering medical insight and efficient transformation, high clinical value mining and academic promotion, to terminal coverage, investment and BD, full industry chain cost control, professional academic brand building, intelligent digital application and rigid performance management, in order to form a systemic advantage that supports sustainable competition. In order to ensure the implementation of strategic initiatives and capabilities, the company system has consolidated five major organizational guarantees: strengthening the leadership of party building and the "big supervision" system to lay a solid foundation for development; promoting organizational transformation and efficiency, creating a professional talent echelon; promoting efficient internal collaboration, and establishing a performance-oriented salary incentive system to create a selection and replacement mechanism that can be promoted and demoted. These strategic deployments jointly ensure that the company's strategy is penetrated and effectively implemented from planning to execution, driving the company towards high-quality development.

Forward-looking statements and expectations such as future plans, development goals, and strategic initiatives involved in the company's strategic planning do not constitute any substantive commitment by the company to investors. In view of the fact that the macroeconomic environment, business development situation, market competition pattern and company operating conditions may continue to change, the company may make appropriate adjustments to this plan based on policy adjustments, industry changes, competition patterns and actual operation and development needs. Investors are kindly requested to pay attention to investment risks.

The proposal has been reviewed and approved at the first working meeting of the Strategy and ESG Committee of the Board of Directors in 2026.

The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

2. 2025 Board of Directors Work Report

The voting results were: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions. This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

3. 2025 Audit Committee Performance Report

This proposal has been reviewed and approved by the first working meeting of the Audit Committee of the Board of Directors in 2026.

The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

4. Special opinions on the evaluation of the independence of current independent directors

For details, please refer to the "Special Opinions on the Assessment of the Independence of Incumbent Independent Directors" published by the company on the Shanghai Stock Exchange website (www.sse.com.cn).

The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

5. 2025 Financial Final Accounts Report

This proposal has been reviewed and approved by the first working meeting of the Audit Committee of the Board of Directors in 2026.

The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

6. Profit distribution plan for 2025

For details, please refer to the "Announcement on the Profit Distribution Plan for 2025" issued by the company on the Shanghai Stock Exchange website (www.sse.com.cn) (Announcement No. Lin 2026-005).

7. Full text and summary of "2025 Annual Report"

For details, please refer to the full text and summary of the "2025 Annual Report" published by the company on the Shanghai Stock Exchange website (www.sse.com.cn).

This proposal has been reviewed and approved by the first working meeting of the Audit Committee of the Board of Directors in 2026.

The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

8. 2025 Sustainable Development and ESG Report

For details, please refer to the "2025 Sustainability and ESG Report" published by the company on the Shanghai Stock Exchange website (www.sse.com.cn).

This proposal has been reviewed and approved at the first working meeting of the Strategy and ESG Committee of the Board of Directors in 2026. The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

9. 2025 Internal Control Evaluation Report

For details, please refer to the "2025 Internal Control Evaluation Report" published by the company on the Shanghai Stock Exchange website (www.sse.com.cn).

This proposal has been reviewed and approved by the first working meeting of the Audit Committee of the Board of Directors in 2026.

The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

10. Proposal on the 2025 Internal Audit Work Report and the 2026 Internal Audit Plan

This proposal has been reviewed and approved by the first working meeting of the Audit Committee of the Board of Directors in 2026.

The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

11. Proposal on applying for a comprehensive credit line from the bank

In view that the company's bank comprehensive credit line is about to expire, in order to ensure the company's capital needs and reduce financing costs, and taking into account the company's capital status and business needs, the company plans to apply to the bank for a comprehensive credit line totaling no more than RMB 10.7 billion. The details of the credit limit to be applied for are as follows:

Serial number Credit granting bank Credit limit (100 million yuan) 1 China Construction Bank Co., Ltd. Tianjin Branch or its branches 25

2 Agricultural Bank of China Co., Ltd. Tianjin Branch or its branches 16

Shanghai Pudong Development Bank Co., Ltd. Tianjin Branch or its branches

3 11

structure

4 Export-Import Bank of China Tianjin Branch 10

5 Tianjin Branch of China Minsheng Banking Corporation or its branches 9

6 China CITIC Bank Tianjin Branch or its branches 6

7 Industrial and Commercial Bank of China Limited Tianjin Branch or its branches 5

8 Bank of China Co., Ltd. Tianjin Branch or its branches 5

9 Zheshang Bank Co., Ltd. Tianjin Branch or its branches 5

10 China Development Bank Tianjin Branch 4

11 Industrial Bank Co., Ltd. Tianjin Branch or its branches 4

12 China Merchants Bank Co., Ltd. Tianjin Branch or its branches 3

13 Mizuho Bank (China) Co., Ltd. Tianjin Branch 2

14 Postal Savings Bank of China Tianjin Branch or its branches 2

Total 107

The comprehensive credit business scope includes but is not limited to working capital loans, issuance of bank acceptance bills, issuance of letters of credit, etc. The credit method is credit-based and does not involve mortgage or guarantee. The final credit limit is subject to the actual approved limit by the bank, and the credit limit can be used repeatedly. The above-mentioned credit limit is not equal to the actual financing amount. The specific financing amount is determined based on the company's actual capital needs within the comprehensive credit limit. The specific credit period and financing period shall be subject to the period agreed in the contract.

After the board of directors approves this proposal, it is recommended that the company's management be authorized to handle relevant procedures and sign various relevant documents on behalf of the company within the above quota and period. The authorization period is within 12 months from the date of review and approval by the board of directors. The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

12. Proposal on Provision for Impairment of Various Assets in 2025

For details, please refer to the "Announcement on the Provision for Impairment of Various Assets in 2025" published by the company on the Shanghai Stock Exchange website (www.sse.com.cn) (Announcement No.: Lin 2026-006).

This proposal has been reviewed and approved by the first working meeting of the Audit Committee of the Board of Directors in 2026.

The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

13. 2025 Accounting Firm Performance Evaluation Report

For details, please refer to the "2025 Accounting Firm Performance Evaluation Report" published by the company on the Shanghai Stock Exchange website (www.sse.com.cn).

This proposal has been reviewed and approved by the first working meeting of the Audit Committee of the Board of Directors in 2026.

The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

14. Proposal on the performance appraisal results of the company and managers in 2025

This proposal has been reviewed and approved by the first working meeting of the Nomination, Remuneration and Assessment Committee of the Board of Directors in 2026. The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.

15. Proposal on the Company’s Total Wage Management Measures

16. Proposal on Performance Management Measures for Company Managers

17. Proposal on the Remuneration Management Measures for the Company’s Management Members

18. Proposal on Annual Remuneration of Directors and Senior Management

For details, please refer to the "2025 Annual Report" published by the company on the Shanghai Stock Exchange website (www.sse.com.cn).

This proposal has been submitted to the first working meeting of the Nomination, Remuneration and Appraisal Committee of the Board of Directors in 2026. Related committee members Mr. Xu Ning and Mr. Han Xiutao abstained from voting. Since the number of non-related committee members is less than half, this proposal is directly submitted to the company's board of directors for review.

Related directors Mr. Cai Jinyong, Mr. Xi Kai, Ms. Wang Aijian, Mr. Han Xiutao, Mr. Duan Yalin, Mr. Xu Ning and Mr. Ye Lin abstained from voting. The remaining eight directors all voted. The voting results were: 8 valid votes, including: 8 votes in favor, 0 votes against, and 0 abstentions. This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

19. Proposal on signing cooperation agreement and related transactions

For details, please refer to the "Announcement on the Signing of Cooperation Agreement and Related Transactions" issued by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) (Announcement No. Lin 2026-007).

This proposal has been reviewed and approved at the first special meeting of independent directors in 2026.

The associated director Mr. Cai Jinyong abstained from voting, and the remaining fourteen directors all voted. The voting results were: 14 valid votes, including: 14 votes in favor, 0 votes against, and 0 abstentions.

Announcement is hereby made.

Tasly Pharmaceutical Group Co., Ltd. Board of Directors

March 20, 2026